COVID-19 in Liver Transplant Recipients

Ravina Kullar¹, Ankur Prakash Patel² and Sammy Saab²

¹Expert Stewardship, Inc., Newport Beach, CA, USA; ²David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA

Abstract

Background and Aims: Coronavirus disease 2019 (COVID-19) has infected over 93 million people worldwide as of January 14, 2021. Various studies have gathered data on liver transplant patients infected with COVID-19. Here, we discuss the presentation of COVID-19 in immunosuppressed patients with prior liver transplants. We also evaluate patient outcomes after infection. Methods: We searched the PubMed database for all studies focused on liver transplant patients with COVID-19. Results: We identified eight studies that evaluated COVID-19 infection in liver transplant patients (n=494). Hypertension was the most prevalent comorbidity in our cohort. Calcineurin inhibitors were the most common immunosuppressant medications in the entire cohort. The average time from liver transplant to COVID-19 infection in our cohort was 74.1 months. Fever and cough, at 70% and 62% respectively, were the most common symptoms in our review. In total, 50% of the patients received hydroxychloroquine as treatment for COVID-19. The next most prevalent treatment was azithromycin, given to 30% of patients in our cohort. In total, 80% of the patients were admitted to a hospital and 17% required intensive care unit-level care, with 21% having required mechanical ventilation. Overall mortality was 17% in our review. Conclusions: Given the immunocompromised status of liver transplant patients, more intensive surveillance is necessary for severe cases of COVID-19 infection. As liver transplantations have been restricted during the COVID-19 pandemic, further investigation is warranted for studying the risk of COVID-19 infection in liver transplant patients.

Citation of this article: Kullar R, Patel AP, Saab S. COVID-19 in liver transplant recipients. J Clin Transl Hepatol 2021;9(4):545–550. doi: 10.14218/JCTH.2020.00098.

Keywords: COVID-19; Liver transplantation; Immunosuppression.

Abbreviations: AASLD, American Association for Study on Liver Diseases; ACE2, angiotensin-converting enzyme 2; AZM, azithromycin; CDC, Center for Disease Control and Prevention; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; DM, diabetes mellitus; HCV, hepatitis C virus; HTN, hypertension; ICU, intensive care unit; IFN-B, interferon-beta; MMF, mycophenolate mofetil; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; SOT, solid organ transplantation; TOX, tocilizumab; WHO, World Health Organization.

*Correspondence to: Sammy Saab, Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, CA 90095, USA. Tel: +1-310-206-6705, Fax: +1-310-206-4197, E-mail: SSAab@mednet.ucla.edu

Introduction

The coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has resulted in over 107 million documented cases globally and close to 2.5 million deaths, as of February 10, 2021. On March 11, 2020, the World Health Organization (WHO) classified COVID-19 as a pandemic. The severity of COVID-19 in the general population ranges from asymptomatic/mild symptoms to critically ill in a proportion of patients. The Centers for Disease Control and Prevention (CDC) has recognized that those with certain underlying medical conditions are at increased risk for severe illness from COVID-19, including cancer, chronic kidney disease, liver disease, chronic obstructive pulmonary disease, obesity, type 2 diabetes mellitus, serious heart conditions, respiratory diseases, and immunocompromised status, including those requiring immunosuppression following solid organ transplantation (SOT).

Accordingly, liver transplantation is the second most common SOT globally after kidney transplantation, with the overall rate reported at 3.7 per million population. In developed countries, hepatitis C virus (commonly known as HCV) is the primary reason for liver transplant; however, HCV is now being replaced by alcoholic liver disease, non-alcoholic liver disease, and hepatocellular carcinoma. Based on familiarity with viral respiratory infections in patients with SOT, the clinical presentation of COVID-19 would likely be more severe in these liver transplant recipients, as they are immunosuppressed and, therefore, have a weaker immune system. To date, no donor-derived COVID-19 cases have been reported. Angiotensin-converting enzyme 2 (often referred to as ACE2), which is a receptor for SARS-CoV-2, is present in almost all organs, including the lung, heart, kidney, liver, and intestine. Therefore, SARS-CoV-2 viremia could potentially infect any transplant organ and suppress itself until the immunosuppressed status exists. In a survey conducted in >80 major transplant centers in the USA between March 24 and March 31, 2020, 31 (35.2%) centers reported 148 patients with SOT with COVID-19 overall. Of these patients, 80 (54.1%) were mildly symptomatic, 31 (20.9%) were moderately symptomatic with pneumonia, and 37 (25.0%) were critically ill. These findings suggest a greater disease severity compared with patients without SOT with COVID-19. Further, SOT recipients who have COVID-19 may shed greater amounts of virus for longer durations compared to non-immunosuppressed patients. This has been shown in other viruses as well, such as influenza. In immunocompetent adults, the majority of patients shed influenza for a maximum of 5 days. Conversely, a study of allogeneic hematopoietic stem cell transplant recipients with influenza revealed that the mean duration of viral shedding was 7 days (range: 2–37 days); in those patients...
who received no therapy, the mean duration of shedding was 11.3 days.10

Transplantations have been restricted due to the high risk of serious COVID-19 infection in this population as well as risk of transmission in health care workers. In fact, there has been a steep decline in organ donations and SOT (for kidney, liver, heart, and lung) procedures since the beginning of the COVID-19 pandemic in the USA, decreasing by 51.1%.11 The American Association for Study on Liver Diseases (commonly known as the AASLD) recommends that liver transplantation should be limited to emergency cases (e.g., patients with high model for end-stage liver disease scores) or hepatocellular carcinoma patients who are at risk of disease progression and removal from the waiting list.12

Limited data exist from evaluations of the impact of COVID-19 on liver transplant recipients. In this paper, we review real-world studies evaluating the effect of COVID-19 in liver transplant recipients.

Methods

Search strategy

We searched the PubMed database for all studies focused on liver transplant patients with COVID-19. We used a combination of the keywords 'COVID-19', 'SARS-CoV-2', and 'liver transplant' in our literature search. The PubMed search was limited to articles published on 1/1/2020 or later to ensure the search was more specific to COVID-19 articles only. The search was run on 1/14/2021.

Inclusion and exclusion criteria

We included all studies published in scientific journals that provided information on COVID-19 infection in liver transplant patients. Only studies focused on COVID-19 were included in data collection, and studies discussing SARS, MERS, or other infections were excluded from data collection. Only studies with liver transplant patients were included; papers including non-transplant patients, pediatric papers, and papers without patient data were excluded. Case reports were excluded, as well as papers that did not exclusively focus on liver transplant patients. Only papers with data on five or more patients in their cohort were included. We collected data on country of origin, size of cohort, patient comorbidities, time from liver transplant to COVID-19 infection, immunosuppressant medications, COVID-19 symptoms, COVID-19-specific treatments, hospitalization rate, intensive care unit (ICU) admission rate, need for mechanical ventilation, and mortality rate.

Results

The results of our review of the literature yielded eight studies containing data on liver transplant patients infected with COVID-19 (Fig. 1 and Table 1).13–20 Patients from our review were from Europe, North America, South America, and Asia. Six studies with patients from Europe were included in our analysis.13,15–18,20 The total number of patients in our cohort was 494. The largest study we included had 151 patients.20 The majority of patients were men. The mean patient age was 62.7. Fifty-one percent of patients in our cohort had hypertension as a comorbidity. The next most prevalent comorbidity was diabetes mellitus. Calcineurin inhibitors (CNIs) were the most prevalent immunosuppressant medications among the entire cohort. The next most common immunosuppressant was mycophenolate mofetil (MMF), followed by steroids.

All studies provided data on symptoms, treatments, and outcomes of COVID-19-infected liver transplant patients (Table 2).13–20 The average time from liver transplant to COVID-19 infection in our cohort was 74.1 months. Fever and cough, at 70% and 62% respectively, were the most common symptoms in our review. In total, 50% of patients received hydroxychloroquine (HCQ) as treatment for COVID-19. The next most prevalent treatment was azithromycin, given to 39% of patients in our cohort. Eighty percent of the entire cohort was admitted to a hospital. Seventeen percent of patients required ICU-level care. Twenty-one percent of patients required mechanical ventilation. Overall mortality was 1.7% in our review.13–20

Webb et al20 reported the largest cohort in our review, with 151 liver transplant patients. Of these patients, 82% were admitted, with 28% requiring ICU-level care. Thirty patients required mechanical ventilation, and twenty-eight patients died. Waisberg et al19 reported data on five patients from Brazil with an average time from liver transplant to COVID-19 infection of 0.56 months, which was the shortest in our cohort. All five of those patients had been admitted and died. One study reported data on 38 patients from the USA,19 with 71% of that cohort having been admitted, 21% requiring ICU-level care, and 18% having died.

Discussion

As the COVID-19 pandemic continues to spread and impact the entire world, SOT recipients are at high risk of infection and poor outcomes due to high rates of pre-existing conditions in addition to chronic immunosuppression. Here, we provide one of the largest reviews of COVID-19 in liver transplant recipients. With a median age of 64 years, over 50% and 40% of patients had hypertension and diabetes, respectively, as a comorbidity. The most common immunosuppressive agents used were CNIs (82%), MMF (39%), and steroids (26%). There are inadequate data on the relationship between immunosuppressive therapy and COVID-19
Table 1. Demographic data of COVID-19-infected liver transplant patients

| Study | AuthorRef | Country | Cohort Size | Age | Sex, M/F | Comorbidities | Immunosuppressant regimen* |
|-------|------------|---------|-------------|-----|---------|---------------|----------------------------|
| 1     | Colmenero et al\(^{13}\) | Spain | 111 | Mean 65.3 | 79/32 (71%/29%) | HTN 64 (58%) | CNI 72 (65%) |
| 2     | Waisberg et al\(^{14}\) | Brazil | 5 | Mean 59.6 | 4/1 (80%/20%) | DM 53 (48%) | mTORi 23 (21%) |
| 3     | Becchetti et al\(^{15}\) | Europe\(^{c}\) | 57 | Median 65 | 40/17 (70%/30%) | Cardiovascular 22 (20%) | MMF 57 (51%) |
| 4     | Loinaz et al\(^{16}\) | Spain | 19 | Median 58 | 14/5 (74%/26%) | CKD 0 (0%) | Steroids 24 (22%) |
| 5     | Patrono et al\(^{17}\) | Italy\(^{d}\) | 10 | Mean 65.6 | 8/2 (80%/20%) | Other\(^{b}\) 13 (12%) | Other 0 (0%) |
| 6     | Belli et al\(^{18}\) | Europe (Italy, Spain, France) | 103 | Median 65 | 76/27 (74%/26%) | | |
| 7     | Lee et al\(^{19}\) | US | 38 | Median 63 | 26/12 (68%/32%) | | |
| 8     | Webb et al\(^{20}\) | International\(^{e}\) | 151 | Median 60 | 102/49 (68%/32%) | | |

### Summary

| | Total (n) 494; Average (n) per study 61.8 |
| | Mean 62.7 | Median 64 |

### Comorbidities

| | HTN | DM | Cardiovascular | CKD | Other\(^{b}\) |
|---|---|---|---|---|---|
| | 64 (58%) | 53 (48%) | 22 (20%) | 0 (0%) | 13 (12%) |
| | 32 (56%) | 21 (37%) | 21 (37%) | 0 (0%) | 2 (20%) |
| | 10 (53%) | 6 (32%) | 0 (0%) | 0 (0%) | 18 (32%) |
| | Unknown | Unknown | Unknown | Unknown | Unknown |
| | 52 (50%) | 41 (40%) | 15 (15%) | 15 (15%) | 25 (63%) |
| | 24 (63%) | 18 (47%) | 22 (15%) | 24 (63%) | 2 (5%) |
| | 63 (42%) | 65 (43%) | 76 (16%) | 0 (0%) | 19 (13%) |
| | 248 (51%) | 205 (42%) | 61 (16%) | 55 (11%) | 47 (10%) |

### Immunosuppressant regimen*

| | CNI | mTORi | MMF | Steroids | Other |
|---|---|---|---|---|---|
| | 72 (65%) | 23 (21%) | 57 (51%) | 24 (22%) | 0 (0%) |
| | 5 (100%) | 0 (0%) | 4 (80%) | 5 (100%) | 2 (40%) |
| | 49 (86%) | 6 (11%) | 25 (44%) | 10 (18%) | 1 (2%) |
| | 8 (42%) | 4 (21%) | 7 (37%) | 3 (16%) | 1 (2%) |
| | 10 (100%) | 2 (20%) | 6 (60%) | 3 (30%) | 1 (5%) |
| | 86 (83%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | 38 (100%) | 1 (3%) | 19 (50%) | 15 (39%) | 2 (5%) |
| | 135 (89%) | 7 (5%) | 77 (51%) | 67 (44%) | 13 (9%) |
| | 403 (82%) | 43 (9%) | 195 (39%) | 127 (26%) | 17 (3%) |

### Abbreviations

HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; mTORi, mammalian target of rapamycin inhibitors.

*Immunosuppressant regimens were grouped as follows: CNI included tacrolimus and cyclosporine; mTORi included everolimus and sirolimus; MMF included MMF and mycophenolic acid; steroids included steroids; and other included basiliximab, anti-thymocyte globulin, and azathioprine.

*Other* included "pulmonary", pulmonary arterial hypertension, "bronchopulmonary", "respiratory", hyperlipidemia, and malignancy.

*Becchetti et al did not specify which countries in Europe their data came from.

*Patrono et al did not provide any data on comorbidities.

*Webb et al collected data from 18 countries, namely the USA, UK, an unspecified Middle East country, Italy, Mexico, Canada, Sweden, Belgium, Netherlands, Brazil, Switzerland, Germany, Egypt, Spain, Greece, India, Philippines, Portugal, and Turkey.
| Study | Summary |
|-------|---------|
| 1     | 2       | 3       | 4       | 5       | 6       | 7       | 8       |
| Author | Colmenero et al.\(^3\) | Waisberg et al.\(^4\) | Becchetti et al.\(^5\) | Loinaz et al.\(^6\) | Patrono et al.\(^7\) | Belli et al.\(^8\) | Lee et al.\(^9\) | Webb et al.\(^10\) |
| Country | Spain | Brazil | Europe | Spain | Italy | Europe (Italy, Spain, France) | US | International |
| Cohort Size | 111 | 5 | 57 | 19 | 10 | 103 | 38 | 151 |
| Average time from transplant to COVID-19 infection | 105 months | 0.56 months | 72 months | 83 months | 85 months | Unknown\(^c\) | 45.6 months | 60 months | Average: 74.1 months |
| Symptoms |  |  |  |  |  |  |  |  |  |
| Fever | 83 (75%) | 4 (80%) | 44 (77%) | 8 (42%) | 6 (60%) | 71 (69%) | 23 (61%) | Unknown\(^d\) | 239 (70%) |
| Cough | 78 (70%) | 2 (40%) | 31 (54%) | 16 (84%) | 3 (30%) | 60 (58%) | 21 (55%) | Unknown\(^d\) | 211 (62%) |
| Dyspnea | 46 (41%) | 4 (80%) | 26 (46%) | 9 (47%) | 1 (10%) | 35 (34%) | 13 (34%) | Unknown\(^d\) | 134 (39%) |
| GI | 38 (34%) | 1 (20%) | 18 (32%) | 6 (32%) | 1 (10%) | 24 (23%) | 16 (42%) | 45 (30%) | 149 (30%) |
| Treatment |  |  |  |  |  |  |  |  |  |
| HCQ | 88 (79%) | 1 (20%) | 24 (42%) | 11 (58%) | 6 (60%) | 63 (61%) | 18 (47%) | 38 (25%) | 249 (50%) |
| Anti-viral therapy\(^a\) | 41 (37%) | 0 (0%) | 3 (5%) | 2 (11%) | 2 (20%) | 16 (16%) | 0 (0%) | 19 (13%) | 83 (17%) |
| AZM | 60 (54%) | 2 (40%) | 35 (61%) | 0 (0%) | 0 (0%) | 31 (30%) | 18 (47%) | 1 (1%) | 147 (30%) |
| Steroids | 12 (11%) | 0 (0%) | 19 (33%) | 0 (0%) | 3 (30%) | 17 (17%) | 5 (13%) | 0 (0%) | 56 (11%) |
| IFN-B | 3 (3%) | 0 (0%) | 5 (9%) | 2 (11%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 10 (2%) |
| TOZ | 15 (14%) | 0 (0%) | 0 (0%) | 2 (11%) | 0 (0%) | 7 (7%) | 0 (0%) | 2 (1%) | 26 (5%) |
| Hospital course |  |  |  |  |  |  |  |  |  |
| Admitted (n) | 96 (86%) | 5 (100%) | 41 (72%) | 12 (63%) | 9 (90%) | 83 (81%) | 27 (71%) | 124 (82%) | 397 (80%) |
| ICU (n) | 12 (11%) | Unknown\(^b\) | 4 (7%) | 1 (5%) | 0 (0%) | 15 (15%) | 8 (21%) | 43 (28%) | 83 (17%) |
| Ventilation (n) | 22 (20%) | 2 (40%) | 12 (21%) | 2 (11%) | 2 (20%) | 25 (24%) | 8 (21%) | 30 (20%) | 103 (21%) |
| Death (n) | 20 (18%) | 2 (40%) | 7 (12%) | 2 (11%) | 2 (20%) | 16 (16%) | 7 (18%) | 28 (19%) | 84 (17%) |

Abbreviations: AZM, azithromycin; GI, gastrointestinal; IFN-B, interferon-beta; TOZ, tocilizumab.
\(^a\)Antiviral therapy included remdesivir, lopinavir/ritonavir, sofosbuvir, and darunavir/ritonavir.
\(^b\)Waisberg et al did not provide any data on ICU admissions.
\(^c\)Belli et al did not provide any data on average time from transplant to COVID-19 infection.
\(^d\)Webb et al did not provide any data on fever, cough, and dyspnea.
Kullar R. et al.: COVID-19 and liver transplant recipients

in liver transplant recipients with COVID-19. Various studies have shown that CNIs display antiviral effects in vitro against coronaviruses and may also ameliorate the cytokine storm.\(^{21,22}\) Similar to SARS-CoV-2, MMF yields a cytostatic effect on activated lymphocytes; therefore, MMF and SARS-CoV-2 may result in a synergic and damaging outcome on reducing peripheral lymphocytes. Although SOT recipients may be at greater risk for COVID-19 due to immunosuppressive therapy, there are still no definitive data to suggest that the immunosuppressive protocol be altered. For patients with mild to moderate COVID-19, it is advised that immunosuppression be continued;\(^{25}\) however, if there is fever, lymphopenia, or worsening of the patient's pneumonia, reducing the dose of azathioprine or MMF should be considered.\(^{26}\) Patients with severe COVID-19 may need their dose of CNI reduced. Further research evaluating the role of immunosuppressive agents and COVID-19 is warranted.

As in the general population, the most common symptoms patients had were fever and cough. However, there were also other presentations, including digestive symptoms and dyspnea.\(^{27}\) The most common treatment for COVID-19 was HCQ. The paradigm of treatment has evolved rapidly, with HCQ no longer being recommended for the treatment of COVID-19. We revealed that the overall mortality rate in liver transplant recipients was 17%, which is in alignment with the general population (15–22%).\(^{28,29}\) However, pooled data from various SOT studies report worse outcomes, with the in-hospital case fatality rate ranging from 24% to 27%.\(^{30,31}\)

Several limitations of this study should be noted. The majority of patients in our analysis were from European centers; therefore, generalizability to people from other countries may be limited. Moreover, many of the studies included patients treated with HCQ, which is not currently recommended for the Infectious Diseases Society of America COVID-19 guidelines.\(^ {32}\) The use of HCQ, as it was applied in earlier studies, is considered less efficacious than currently available treatments. Patients included in this study varied in time from liver transplant to COVID-19 infection (ranging from 0.56 to 105 months), leading to variability in study outcomes. Finally, over or under reporting of symptoms in our various cohorts may have contributed to reporting bias.

In conclusion, patients with liver disease and transplant candidates are at risk from COVID-19. Unfortunately, SOT transplant recipients are a highly susceptible population; therefore, clinicians should have an understanding of the disease and take the essential precautions to ensure the safety of liver transplant recipients.

**Funding**

None to declare.

**Conflict of interest**

Ravina Kullar was a former employee of Gilead Sciences. Sammy Saab is on the speaker bureau and honoraria recipient of AbbVie, Bristol Myers Squibb, Bayer, Eisai, Exelixis, Gilead, Intercept, and Salix; Sammy Saab is also an advisor/consultant for AbbVie, Bayer, Eisai, Exelixis, Gilead, Intercept, Mallinckrodt, and Salix. The other author has no conflict of interests related to this publication.

**Author contributions**

Study concept and design (RK, SS), acquisition of data (RK, APP), analysis and interpretation of data (RK, APP, SS), drafting of the manuscript (RK, APP, SS), critical revision of the manuscript for important intellectual content (RK, APP, SS), statistical analysis (APP), administrative, technical, or material support; study supervision (SS).

**References**

1. COVID-19 coronavirus pandemic. Available from: https://www.worldometers.info/coronavirus/.

2. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed at 11 March 2020.

3. Centers for Disease Control and Prevention. People with certain medical conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.

4. Carmona M, Álvarez M, Marco J, Mahilbo B. Organ donation and transplant activities, 2015 report. Available from: http://www.transplant-observatory.org/download/organ-donation-transplant-activities-2015-report-2/. Accessed at September 2017.

5. Trotter JF, Cárdenas A. Liver transplantation around the world. Liver Transpl 2016;22:1059–1061. doi:10.1002/lt.24508.

6. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215–220. doi:10.1038/s41586-020-2298-x.

7. Boyarsky BJ, Po-Yu Chiango T, Werbel WA, Durand CM, Avery RK, Getzin SN, et al. Early impact of COVID-19 on transplant outcomes and policies in the United States. Am J Transplant 2020;20:1809–1818. doi:10.1111/ajt.15915.

8. Manuel O, Estabrook M. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplant Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13511. doi:10.1111/ctr.13511.

9. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240–1246. doi:10.1001/jama.282.13.1240.

10. Nichols WG, Guthrie KA, Corey L, Boekhout M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004;39:1300–1306. doi:10.1086/425604.

11. Loupy A, Aubert O, Reese PP, Bastien O, Bayer F, Jacquelinet C. Organ procurement and transplantation during the COVID-19 pandemic. Lancet 2020;395:e95–e96. doi:10.1016/S0140-6736(20)31040-0.

12. Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic. Available from: https://www.aasld.org/sites/default/files/2020-03/AASLD-COVID19-ClinicalInsights-FINAL-3.23.2020.pdf.

13. Colmenero J, Rodríguez-Perelvazerí M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol 2021;74:148–155. doi:10.1016/j.jhep.2020.07.040.

14. Waisberg DR, Abdala E, Nacif LS, Haddad LB, Ducatti L, Santos VR, et al. Liver transplant recipients infected with SARS-CoV-2 in the early postoperative period: Lessons from a single center in the context of the pandemic. Transpl Infect Dis 2020:e13418. doi:10.1111/tid.13418.

15. Becceatti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: a preliminary report from Northwestern Italy. Transpl Infect Dis 2020;22:e13353. doi:10.1111/tid.13353.

16. Bollß LS, Duvoux C, Karam Y, Adam R, Cuervas-Mons V, Pasulo L, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol 2020;5:724–725. doi:10.1016/S2468-1253(20)30183-7.

17. Lee BT, Perumalswami PV, IM GV, Florman S, Schiano TD. COVID-19 in liver transplant recipients: An initial experience from the US epicenter. Gastroenterology 2020;159:1176–1178.e2. doi:10.1053/j.gastro.2020.05.050.

18. Webb GJ, Marjot T, Cook JA, Aloman C, Brenner EJ, et al. Outcomes following COVID-19 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020;5:1008–1016. doi:10.1016/S2468-1253(20)30271-5.

19. Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclosporine A in mouse macrophage cells. Immunopharmacology 2013;154:1203–1212. doi:10.1016/j.imapharm.2013.05.001.

20. Allison AC, Eguu EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85–118. doi:10.1016/S0162-3109(00)00188-0.

21. Brennan DC, Legndere C, Patel D, Mange K, Wiland A, McCague K, et al. Cytomegalovirus infection between everolimus versus mycophenolate in
Kullar R. et al: COVID-19 and liver transplant recipients

[25] Liu H, He X, Wang Y, Zhou S, Zhang D, Zhu J, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. Hepatol Int 2020;14:432–436. doi:10.1007/s12072-020-10043-2.

[26] Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic. AASLD Expert Panel Consensus Statement. Hepatology 2020;72:287–304. doi:10.1002/hep.31281.

[27] Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York city. N Engl J Med 2020;382:2372–2374. doi:10.1056/NEJMc2010419.

[28] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5.

[29] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020;323:2052–2059. doi:10.1001/jama.2020.6775.

[30] Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant 2020;20:1849–1858. doi:10.1111/ajt.15929.

[31] Pereira MR, Mohan S, Cohen DJ, Husain SA, Dubé GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant 2020;20:1800–1808. doi:10.1111/ajt.15941.

[32] Bhimraj A, Morgan RL, Shumaker AH, Levergne V, Baden L, Cheng VCC, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/.

[24] de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011;11:2453–2462. doi:10.1111/j.1600-6143.2011.03674.x.